Expertise in
4
conditions

Kuo-hsuan A. Hsu

No. 1650, Sect. 4, Taiwan Boulevard, 407, 
Taitung, TNQ, TW 
Expertise in
4
conditions
No. 1650, Sect. 4, Taiwan Boulevard, 407, 
Taitung, TNQ, TW 
OverviewLocationsClinical Research

Overview

Kuo-hsuan Hsu practices in Taitung, Taiwan. Hsu is highly rated in 4 conditions, according to our data. Their top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

Their clinical research consists of co-authoring 80 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Locations

No. 1650, Sect. 4, Taiwan Boulevard, 407, Taitung, TNQ, Taiwan
Other Locations
No.1650, Sect. 4, Taiwan Boulevard, 407, Taitung, TNQ, Taiwan
No. 1650, Sect. 4, Taiwan Blvd, 407, Taitung, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2

80 Total Publications

Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Journal: Anti-cancer drugs
Published: July 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsu's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile